A phase I study of ACE-2494 in healthy volunteers

Trial Profile

A phase I study of ACE-2494 in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs ACE 2494 (Primary)
  • Indications Musculoskeletal disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Sep 2017 The company expects to initiate this clinical trial in late 2017, accoding to an Acceleron Pharma media release.
    • 03 Nov 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017, as per an Acceleron Pharma media release stating that the company plans to initiate this trial in mid-2017.
    • 04 Aug 2016 According to a company media release, Acceleron plans to initiate this study in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top